DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Astigmatism - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Astigmatism - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
Astrocytoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Astrocytoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
Ataxia - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Ataxia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and...
January 2022
60 pages
Ataxia Telangiectasia (AT) - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Ataxia Telangiectasia (AT) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dise...
January 2022
60 pages
ATR protein inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 2-3 Business Days DelveInsight’s, “ATR protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 9+ companies and 9...
January 2022
60 pages
Atrial Flutter - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Atrial Flutter - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histori...
January 2022
60 pages
Atrophic Vaginitis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Atrophic Vaginitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, his...
January 2022
60 pages
Aurora-A kinase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 hours DelveInsight’s, “Aurora-A kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pip...
January 2022
60 pages
Autoimmune Encephalitis (AE) - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Autoimmune Encephalitis (AE) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the di...
January 2022
60 pages
Autoimmune Gastritis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Autoimmune Gastritis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Autoimmune Hepatitis - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Autoimmune Hepatitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Autophagy Modulators - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Autophagy Modulators - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Avascular Necrosis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Avascular Necrosis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, his...
January 2022
60 pages
Axillary Hyperhidrosis - Epidemiology Insight - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Axillary Hyperhidrosis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
B-Cell Non-Hodgkin Lymphoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'B-Cell Non-Hodgkin Lymphoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dis...
January 2022
60 pages
Bacterial Skin Diseases - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Bacterial Skin Diseases - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease...
January 2022
60 pages
Barett Esophagus - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Barett Esophagus - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histo...
January 2022
60 pages
Basal Cell Neoplasms - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Basal Cell Neoplasms - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
